market perform
reason report
aml threat/safeti concern overst focu shift mtap
upgrad op
bottom line follow earn anticip rebound
investor sentiment driven arriv new ceo jacqualyn
fous realiz stock reaction competit
safeti concern acut myeloid leukemia aml like
overst medacorp kol believ idh agent
continu major role aml even rapid adopt
mp venetoclax front line furthermor
specialist see differenti syndrom manag
often indic respons drug continu
believ progress compani solid tumor pipelin
key unlock valu longer term current level
think investor pay littl option numer
program investor re-engag ahead number
upcom catalyst focu shift away aml concern
maintain pt upgrad op mp
solid commerci perform allevi near-term aml
overhang report tibsovo net product revenu
royalti revenu sale idhifa suggest
agent significantli impact safeti issu
differenti syndrom competit venclexta fear
exit annual hematolog meet base convers
medacorp kol believ idh agent continu
signific role aml despit impact venclexta specif
see emerg mainten therapi studi
phase trial key potenti driver
focu shift solid tumor program mtap current
level think reflect share still think pipelin
critic long-term view compani current
level think investor pay littl number program
near-term catalyst pivot data phase claridhi trial
tibsovo cholangiocarcinoma expect
possibl snda agio present pre-clin data
inhibitor mtap delet tumor american associ
delet repres signific opportun tumor
believ data valid mechan action show target
engag could rais profil program expect
on-going phase basket trial solid tumor lymphoma final
intend present glioma data periop trial
data key compani decis initi phase trial
vorasidenib see data drive
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page import disclosur price chart analyst certif
investor sentiment program
chang model reflect competit venetoclax
incorpor mainten updat model
quarter includ minor adjust expens estim
incorpor aml mainten idhifa tibsovo
separ opportun lower estim number
treatment elig elderli aml patient account newer
tibsovo opportun patient elig standard therapi
also reduc penetr idh agent treatment
elig elderly/unfit patient account expect competit
venclexta chang materi impact valuat
maintain pt
rate inc share outperform pt agio
commerci stage biotechnolog compani two commerci product one wholli own
anoth partner celgen compani focu drug alter cellular metabol
number therapeut area hematolog oncolog view share current level
reflect signific concern competit aml venetoclax believ
overdon continu believ progress compani solid tumor pipelin key
unlock valu longer term current level think investor pay littl
option numer program
chang model follow earn
updat model reflect financi result incorpor modest
adjust expens forecast also made chang long-term
aml forecast specif model frontlin mainten independ tibsovo
idhifa consid separ opportun frontlin induct therapi
lower estim number elderli aml patient treatment elig
account tibsovo opportun patient elig standard therapi
also reduc penetr idh inhibitor frontlin treatment-elig elderly/unfit patient
account expect competit set venetoclax net result
chang lower peak revenu estim model chang materi
impact valuat maintain pt
use risk-adjust sum-of-the-part methodolog valu agio examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener one agio asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/shareww idhifa royalti r/r mut idhifa royalti mut tibsovo sale r/r mut tibsovo sale mut tibsovo sale mut aml tibsovo mitapivat pan-idh clinic preclin asset count total risk-adjust equiti valu risk non-deplet profitabilityagio pharmaceut idhifa royalti r/r mut amlww idhifa royalti mut amlww tibsovo sale r/r mut amlww tibsovo sale mut amlww tibsovo sale mut aml tibsovo cholangiocarcinomaww mitapivat pkdww pan-idh gliomaearli clinic preclin pipelin inc
clinic risk agio numer clinic trial on-going pipelin asset trial
fail either safeti efficaci reason would repres risk current valuat
regulatori risk even agio clinic trial success regulatori approv still need
commerci compani drug failur obtain time regulatori approv repres risk
current valuat
acquisit possibl agio acquir larg pharma biotechnolog compani
signific premium current level repres potenti upsid risk current rate
 mn except per share data
total net
net incom tax
balanc sheet mn
compani report svb leerink partner
